Withdrawal of ‘Xigris’ from the market: old and new lessons
- 1Servizio Anestesia e Rianimazione, Ospedale Civile San Martino, Belluno, Italy
- 2Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccó, in Ranica, Bergamo Italy
- 3Mario Negri Institute headquarters, Milano, Italy
- Correspondence to Dr Guido Bertolini, GiViTI Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò, Ranica, Bergamo 24020, Italy;
Contributors The authors have substantially contributed to drafting and revising the article. All authors approved the final version of the manuscript.
Drotrecogin alfa (activated), Xigris, was licensed in 2001 by the Food and Drug Administration (FDA) and in 2002 by the European Medicine Agency (EMA) for the treatment of severe sepsis and septic shock. The FDA approval process was marked by conflicting opinions during the Anti-Infective Drugs Advisory Committee meeting, where many concerns with regard to the Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial, the study on which the approval was based, were raised.1 In the attempt to follow some of the criticisms, the approval was restricted to a subgroup of the study population that was not predefined, so violating well-known methodological rules and guidelines established by the FDA itself.2 The EMA approved the drug following a similar biased approach. Both regulatory agencies recognised efficacy and safety issues the drug increased the number of severe bleedings, and required post-marketing studies to support the licensing. These studies failed in confirming the first positive results,3 4 but their findings were …